CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
about
First-in-human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse after Transplantation.The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation.Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New Insights from Primary Immunodeficiency.IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production.Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells.One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapyInterleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency ReversalEpigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
P2860
Q49791810-88C70E37-DEC6-4390-A00B-B7A292D82A46Q52560280-0604B895-EC87-4AD3-ABAC-D9FA8E1FC954Q52603962-227A4EB3-F05D-4687-8374-9F989A9F70EDQ52643680-F0678058-277B-4676-9515-F4BDFDF7C45EQ54264715-3DF2D773-462B-44DE-9402-4C161937DDC2Q54938436-388A149A-96BA-48A6-A83C-6B47ADAEE8E5Q55332380-D67862E1-40BA-41EC-8FEC-4FE441C4647EQ56892924-8D9F74BC-94B4-45A0-869C-A28832268B1AQ57425155-90D5EEC5-DFF6-4B8D-9B81-F97716B90BA4Q58130496-4C5C2F91-1422-4D7D-99C5-157245641CC9
P2860
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
@en
type
label
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
@en
prefLabel
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
@en
P2093
P2860
P356
P1476
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
@en
P2093
Aaron R Ireland
Brea A Jewell
Dennis Clement
Devika Jaishankar
Hing C Wong
Jeffrey W Leong
Jodie Goodridge
Julia A Wagner
Justin A King
Karl-Johan Malmberg
P2860
P304
P356
10.1172/JCI90387
P407
P577
2017-10-03T00:00:00Z